May 12, 2021

Remdesivir for Coronavirus Disease 2019 (COVID-19): A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A systematic review and meta-analysis of 5 randomized placebo-controlled trials (n=7,540 total participants) found no significant evidence that remdesivir (100 mg over 10 days) reduced all-cause mortality (RR=0.94, CI 0.82-1.07), clinical progression (RR=1.08, CI 0.99-1.18), or diarrhea (RR=0.82, CI 0.40-1.66). The authors conducted a trial sequential analysis and found that the meta-analysis was underpowered to detect a 10% reduction in all-cause mortality at 0% sample heterogeneity and 11% baseline risk (required n=24,281).

Okoli et al. (May 11, 2021). Remdesivir for Coronavirus Disease 2019 (COVID-19): A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Infectious Diseases. https://doi.org/10.1080/23744235.2021.1923799